ノバルティスが後援するサバトリマブ(MBG453)試験を以前に完了し、治験責任医師がサバトリマブによる継続治療の恩恵を受けると判断した患者に対するロールオーバー試験。
ノバルティスが後援するサバトリマブ(MBG453)試験を以前に完了し、治験責任医師がサバトリマブによる継続治療の恩恵を受けると判断した患者を対象とした非盲検、多施設共同、ロールオーバー試験。
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
調査の概要
状態
詳細な説明
This is a multicenter, open label, roll-over study to collect and assess safety of sabatolimab in participants who are treated in current Novartis-sponsored parent studies and who are benefiting from continued study treatment including sabatolimab as judged by the investigator.
There is no conventional screening period in this study as participants are expected to transition directly from treatment on the parent protocol to treatment on this roll-over protocol. Participants who are candidates for the roll-over protocol will be evaluated by the investigator in the parent protocol for eligibility for the roll-over protocol. If eligible, the parent protocol end of treatment visit will be performed and the informed consent for the roll-over protocol will be signed. Participants then continue treatment on this protocol with the next planned dose of sabatolimab as monotherapy or with other combination agent(s).
The treatment with sabatolimab and combination agent(s), as applicable, is continued according to the schedule in the parent study. Adverse events (AEs) will be collected continuously throughout the study and participants will be questioned about adverse events at each visit.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Oregon Health Sciences University
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112-0550
- Huntsman Cancer Institute Univ of Utah
-
-
-
-
BS
-
Brescia、BS、イタリア、25123
- Novartis Investigative Site
-
-
FI
-
Florence、FI、イタリア、50134
- Novartis Investigative Site
-
-
GE
-
Genova、GE、イタリア、16132
- Novartis Investigative Site
-
-
MI
-
Milan、MI、イタリア、20162
- Novartis Investigative Site
-
-
RM
-
Roma、RM、イタリア、00133
- Novartis Investigative Site
-
-
-
-
Victoria
-
Clayton、Victoria、オーストラリア、3168
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 1M9
- Novartis Investigative Site
-
-
-
-
-
Alexandroupoli、ギリシャ、681 00
- Novartis Investigative Site
-
Pátrai、ギリシャ、265 04
- Novartis Investigative Site
-
-
-
-
-
Zurich、スイス、8091
- Novartis Investigative Site
-
-
-
-
-
Barcelona、スペイン、08036
- Novartis Investigative Site
-
Madrid、スペイン、28009
- Novartis Investigative Site
-
-
Barcelona
-
Badalona、Barcelona、スペイン、08916
- Novartis Investigative Site
-
-
-
-
-
Prague、チェコ、128 08
- Novartis Investigative Site
-
-
-
-
-
Izmir、トルコ(Türkiye)、35100
- Novartis Investigative Site
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau、Baden-Wurttemberg、ドイツ、79106
- Novartis Investigative Site
-
-
-
-
-
Toulouse、フランス、31059
- Novartis Investigative Site
-
-
-
-
Santa Catarina
-
Florianópolis、Santa Catarina、ブラジル、88020-210
- Novartis Investigative Site
-
-
-
-
-
Kuala Lumpur、マレーシア、59100
- Novartis Investigative Site
-
-
-
-
-
Tianjin、中国、300020
- Novartis Investigative Site
-
-
Jilin
-
Changchun、Jilin、中国、130021
- Novartis Investigative Site
-
-
-
-
-
Fukushima、日本、9601295
- Novartis Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participant is currently enrolled in a Novartis-sponsored study with sabatolimab, is being treated with sabatolimab, and has fulfilled all requirements in the parent study.
- Participant is currently benefiting from the treatment with sabatolimab as determined by guidelines of the parent protocol and investigator's judgment.
- Participant has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plan and any other study procedures.
- Written informed consent obtained prior to enrolling in the roll-over study.
Exclusion Criteria:
- Participants in cohorts or treatment groups not receiving sabatolimab in the parent protocol.
- Participant has been permanently discontinued from sabatolimab treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.
- Participant currently has unresolved toxicities for which sabatolimab dosing has been interrupted in the parent study (participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow sabatolimab dosing to resume).
- Pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a female after conception confirmed by a positive serum hCG laboratory test and until the termination of gestation.
- Participant not willing to comply with the contraception requirements outlined in the exclusion criteria of the parent protocol.
- Local access to commercially available sabatolimab for parent protocol indications.
Other protocol-defined Inclusion/Exclusion may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:sabatolimab + azacitidine
Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w. |
Solution for intravenous infusion
他の名前:
Solution for subcutaneous injection or intravenous infusion |
|
実験的:sabatolimab + decitabine
Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v. |
Solution for intravenous infusion
他の名前:
Solution for intravenous infusion |
|
実験的:sabatolimab + venetoclax + azacitidine
Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w. |
Solution for intravenous infusion
他の名前:
Solution for subcutaneous injection or intravenous infusion Tablet for oral administration |
|
実験的:sabatolimab + spartalizumab + decitabine
Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w. |
Solution for intravenous infusion
他の名前:
Solution for intravenous infusion Solution for intravenous infusion
他の名前:
|
|
実験的:sabatolimab + HMA
Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine. |
Solution for intravenous infusion
他の名前:
Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral) |
|
実験的:sabatolimab
Patients will take sabatolimab 800 mg i.v q4w. |
Solution for intravenous infusion
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠:5 years
|
An AE is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. An AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria: fatal, life-threatening, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, may have caused a congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage. |
5 years
|
|
Severity of AEs and SAEs
時間枠:5 years
|
Severity of AEs and SAEs will be measured according to the CTCAE v5.0 |
5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of exposure to sabatolimab
時間枠:5 years
|
The length of time patients will be exposed to sabatolimab and will be reported by treatment groups. |
5 years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CMBG453B12206B
- 2021-004422-30 (EudraCT番号)
- 2024-515281-14-00 (レジストリ識別子:EU CTIS)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。